Search Result

Isoforms Recommended:	SIRT6

Results for "

SIRT6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (4) Autophagy (1) c-Myc (1) Cytochrome P450 (1) ERK (2) Fluorescent Dye (1) FXR (1) GLUT (1) HBV (2) HDAC (3) Histone Demethylase (1) Interleukin Related (2) mTOR (1) NF-κB (1) P2X Receptor (1) p38 MAPK (1) PROTACs (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Ribosomal S6 Kinase (RSK) (1) Sirtuin (25) Small Interfering RNA (siRNA) (3) TNF Receptor (1)
By Research Areas:	Cancer (17) Endocrinology (1) Infection (2) Inflammation/Immunology (8) Metabolic Disease (9) Neurological Disease (4)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107454

OSS_128167 Maximum Cited Publications 31 Publications Verification	Sirtuin HBV	Infection Metabolic Disease Inflammation/Immunology Cancer
OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC₅₀s of 89 μM, 1578 μM and 751 μM for *SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV* activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects .

HY-N0010

Geniposidic acid 5+ Cited Publications	FXR Sirtuin TNF Receptor Interleukin Related	Metabolic Disease
Geniposidic acid is an orally active FXR modulator and *SIRT6* activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .

HY-119376

MDL-800 1 Publications Verification	Sirtuin	Cancer
MDL-800 is an allosteric and selective *SIRT6* activator. MDL-800 increases SIRT6 deacetylation activity with an EC₅₀ of 10.3 µM .

HY-148712

SIRT6 activator 12q	Apoptosis Sirtuin	Cancer
SIRT6 activator 12q is potent, selective and orally active *SIRT6* activator with IC₅₀ values of 171.20, >200, >200, >200, 0.58 μM for SIRT1, SIRT2, SIRT3, SIRT5, SIRT6, respectively. SIRT6 activator 12q inhibits cell growth and migration. SIRT6 activator 12q induces Apoptosis and cell cycle arrest at G2 phase. SIRT6 activator 12q shows anticancer activity .

HY-115453

UBCS039 15+ Cited Publications	Sirtuin Autophagy	Cancer
UBCS039 is the first synthetic, specific Sirtuin 6 (SIRT6) activator, inducing autophagy in human tumor cells, with an EC₅₀ of 38 μM .

HY-RS12950

SIRT6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Sirtuin	Others
SIRT6 Human Pre-designed siRNA Set A contains three designed siRNAs for SIRT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SIRT6 Human Pre-designed siRNA Set A SIRT6 Human Pre-designed siRNA Set A

HY-103721

SIRT6-IN-2	Sirtuin	Metabolic Disease Inflammation/Immunology Cancer
SIRT6-IN-2 (Compound 5) is a selective and competitive *SIRT6* inhibitor (IC₅₀: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects .

HY-156027

SIRT6-IN-3	Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK	Neurological Disease Inflammation/Immunology Endocrinology Cancer
SIRT6-IN-3 (compound 8a) is a selective inhibitor of *SIRT6* (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .

HY-156757

MDL-811	Sirtuin Interleukin Related Cytochrome P450	Neurological Disease Inflammation/Immunology Cancer
MDL-811 is a selective allosteric activator of *SIRT6* with an EC₅₀ of 5.7 μM. MDL-811 possesses anti-inflammatory, antitumor, and neuroprotective activities. MDL-811 can be used for the research of diseases such as colorectal cancer and ischemic stroke .

HY-N5025

Bullatine A	P2X Receptor Apoptosis ERK p38 MAPK c-Myc NF-κB Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Cancer
Bullatine A, a diterpenoid alkaloid, is a potent P2X7 antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting *SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB* pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression .

HY-169159

SIRT6 activator 2	Sirtuin	Metabolic Disease
SIRT6 activator 2 (compound 31) is a sirtuin 6 activator with anti-lipid accumulation properties. SIRT6 activator 2 significantly downregulates LXR, SREBP-1c, and their target genes associated with lipogenesis, and can be used for research related to lipid metabolism-related diseases .

HY-123194

SIRT2/6-IN-1	Histone Demethylase Sirtuin	Metabolic Disease
SIRT2/6-IN-1 (Compound 5) is a *SIRT6/SIRT2* inhibitor, with IC₅₀s of 106 μM and 114 μM. SIRT2/6-IN-1 increases H3K9 acetylation, increases glucose uptake and reduces TNF-α secretion in cells .

HY-168574

SZU-B6	PROTACs Sirtuin Apoptosis	Cancer
SZU-B6 is a PROTAC degrader for *SIRT6* with DC₅₀ of 45 nM and 154 nM in cell SK-HEP-1 and Huh-7. SZU-B6 inhibits the proliferation of cell SK-HEP-1 with an IC₅₀ of 1.51 μM, inhibits the colony formation of SK-HEP-1 and Huh-7, induces apoptosis and arrests the cell cycle at G2/M phase in SK-HEP-1. SZU-B6 exhibits antitumor efficacy in mouse model. (Pink: ligand for target protein (HY-16605); Black: linker (HY-W012935); BLue: ligand for E3 ligase (HY-W453548)

HY-16605

SIRT6-IN-6	Sirtuin GLUT	Metabolic Disease
SIRT6-IN-6 (compound 6d) is a potent and selective *SIRT6* inhibitor with an IC₅₀ of 4.93 μM and a K_i of ~10 μM. SIRT6-IN-6 shows selectivity against other members of the HDAC family (SIRT1-3 and HDAC1-11). SIRT6-IN-6 significantly increases the level of glucose transporter GLUT-1, thereby reducing blood glucose in a mouse model of type 2 diabetes. SIRT6-IN-6 can be used for type 2 diabetes research .

HY-178970

HDAC11-IN-4	HDAC	Cancer
HDAC11-IN-4 is a potent and selective HDAC11 inhibitor with an IC₅₀ of 13.49 nM and a K_i of 2.2 nM. HDAC11-IN-4 exhibits extremely high selectivity for HDAC11 over other defatty-acylases such as SIRT2, SIRT3, SIRT6, and HDAC8 (SI >10,000). HDAC11-IN-4 can be used for the research of cancer .

HY-178990

SIRT6-IN-5	Sirtuin	Cancer
SIRT6-IN-5 (Compound 25) is a selective and safe *SIRT6* inhibitor (IC₅₀ = 18.91 µM). SIRT6-IN-5 can enhance the anti proliferative effect of chemotherapy agents. SIRT6-IN-5 can be used in the research of cancer, such as breast cancer .

HY-RS12952

Sirt6 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Sirt6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sirt6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sirt6 Rat Pre-designed siRNA Set A Sirt6 Rat Pre-designed siRNA Set A

HY-RS12951

Sirt6 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Sirtuin	Others
Sirt6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sirt6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sirt6 Mouse Pre-designed siRNA Set A Sirt6 Mouse Pre-designed siRNA Set A

HY-170402

SIRT6-IN-4	Sirtuin Apoptosis	Cancer
SIRT6-IN-4 (Compound 10d) is a selective inhibitor for *SIRT6* with an IC₅₀ of 5.68 μM. SIRT6-IN-4 inhibits the proliferation of MCF-7 with an IC₅₀ of 8.30 μM. SIRT6-IN-4 arrests the cell cycle at G2/M phase, inhibits thecell migration and invasion of MCF-7, and induces apoptosis. SIRT6-IN-4 exhibits antitumor efficacy in mouse models .

HY-182061

SIRT6 activator 3	Sirtuin	Cancer
SIRT6 activator 3 (Compound 24) is a *SIRT6* activator with an EC₅₀ of 5 μM. SIRT6 activator 3 exhibits histone deacetylation activity. SIRT6 activator 3 can be used in cancer research .

HY-169846

CL5D	Sirtuin	Metabolic Disease
CL5D is an activator of protein deacetylase *SIRT6. CL5D can significantly enhance the deacetylation activity of SIRT6* and improve its catalytic efficiency. CL5D regulates SIRT6 activity by promoting conformational changes, especially dependent on the role of Arg-65 residue. CL5D can be used to study the activation mechanism of SIRT6 and its function in metabolism, DNA repair and aging .

HY-186009

SIRT6 modulator-1	Sirtuin	Neurological Disease
SIRT6 modulator-1 is a *SIRT6* modulator.

HY-177878

IMU-856	Sirtuin	Inflammation/Immunology
IMU-856 is an orally active and systemic action *SIRT6* small molecule regulator. IMU-856 effectively and selectively inhibits the deacetylase activity of SIRT6, while increasing the protein level of SIRT6. IMU-856 can restore intestinal barrier function and can be used for research on celiac disease .

HY-153104

CrBKA	Sirtuin	Cancer
CrBKA is a fluorogenic small-molecule substrate of *SIRT6* with weak activity .

HY-103721R

SIRT6-IN-2 (Standard)	Sirtuin Reference Standards	Metabolic Disease Inflammation/Immunology Cancer
SIRT6-IN-2 (Standard) is the analytical standard of SIRT6-IN-2 (HY-103721). This product is intended for research and analytical applications. SIRT6-IN-2 (Compound 5) is a selective and competitive SIRT6 inhibitor (IC₅₀: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects .

HY-107454R

OSS_128167 (Standard)	Reference Standards Sirtuin HBV	Infection Metabolic Disease Inflammation/Immunology Cancer
OSS_128167 (Standard) is the analytical standard of OSS_128167 (HY-107454). This product is intended for research and analytical applications. OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC₅₀s of 89 μM, 1578 μM and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects .

HY-182412

NH4-6	Sirtuin	Cancer
NH4-6 is a *SIRT2* inhibitor with an IC₅₀ of 0.032 μM against *SIRT2* and an IC₅₀ of 3 μM against *SIRT1. NH4-6 inhibits the deacetylase activity of SIRT1. As a cytotoxic agent, NH4-6 reduces cancer cell viability, suppresses anchorage-independent growth of cancer cells, induces acetylation of α-tubulin, and promotes acetylation of p53*. NH4-6 can be used in the research of breast cancer .

HY-P3364A

Ac-QPKK(Ac)-AMC acetate	Fluorescent Dye Sirtuin HDAC	Others
Ac-QPKK(Ac)-AMC acetate is a p53-derived peptide conjugated with a fluorophore, which serves as a fluorescent peptide substrate for detecting the deacylase activity of zinc-dependent HDACs and sirtuins (Ex = 360 nm; Em = 460 nm) .

Cat. No.	Product Name	Target	Research Area

HY-P3364A

Ac-QPKK(Ac)-AMC acetate	Fluorescent Dye Sirtuin HDAC	Others
Ac-QPKK(Ac)-AMC acetate is a p53-derived peptide conjugated with a fluorophore, which serves as a fluorescent peptide substrate for detecting the deacylase activity of zinc-dependent HDACs and sirtuins (Ex = 360 nm; Em = 460 nm) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0010

Geniposidic acid 5+ Cited Publications	Structural Classification other families Iridoids Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	FXR Sirtuin TNF Receptor Interleukin Related
Geniposidic acid is an orally active FXR modulator and *SIRT6* activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .

HY-N5025

Bullatine A	Alkaloids Piperidine Alkaloids Classification of Application Fields Ranunculaceae Aconitum carmichaeli Debx. Plants Inflammation/Immunology Disease Research Fields Source Classification	P2X Receptor Apoptosis ERK p38 MAPK c-Myc NF-κB Reactive Oxygen Species (ROS)
Bullatine A, a diterpenoid alkaloid, is a potent P2X7 antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting *SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB* pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression .

Species:	Human (2)
Tag:	His (1) GST (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702952

	SIRT6 Protein, Human (GST) SIR2L6	Human	E. coli
	SIRT6 Protein, Human (GST) is the recombinant human-derived SIRT6, expressed by E. coli , with GST labeled tag. ,

HY-P703626

	SIRT6 Protein, Human (His) SIR2L6	Human	E. coli
	SIRT6 Protein, Human (His) is the recombinant human-derived Sirt6, expressed by E. coli , with His labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (1) Rabbit (2)
Reactivity:	Human (3) Rat (2) Mouse (3) Monkey (1)
Application:	IHC-P (2) ICC/IF (3) IP (2) WB (3) FC (1) ELISA (1)
Isotype:	IgG,Kappa (1) IgG (1)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80322

	SIRT6 Antibody (YA078) 1 Publications Verification	WB, ICC/IF, IHC-P, FC	Human, Mouse
	SIRT6 Antibody (YA078) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SIRT6.

HY-P87707

	SIRT6 Antibody (YA7392)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	SIRT6 Antibody (YA7392) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to SIRT6.

HY-P85522

	SIRT6 Antibody (YA5214) 2810449N18Rik; AI043036; Mono ADP ribosyltransferase SIRTuin 6; NAD-dependent protein deacetylase SIRTuin-6; Regulatory protein SIR2 homolog 6; Regulatory protein SIR2 homolog; SIR2 like 6; SIR2 like protein 6; Sir2 related protein type 6; SIR2-like protein 6; SIR2	WB, ICC/IF, IP	Human, Mouse, Rat, Monkey
	SIRT6 Antibody (YA5214) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SIRT6.